Cbd Life Science Stock Price, News & Analysis

CBD Life Sciences (OTC PINK:CBDL) announced a landmark event with the passage of the H.R. 8454 - Medical Marijuana and Cannabidiol Research Expansion Act, signed by both the U.S. House and Senate. This historic legislation creates a new framework for marijuana research, allowing registered entities to manufacture and distribute marijuana for medical purposes. CEO Lisa Nelson emphasized that this opens numerous opportunities as the perception of marijuana and CBD evolves. The bill aims to streamline research processes and remove barriers, promoting the benefits of CBD for various medical conditions.

CBD Life Sciences (OTC PINK:CBDL) announces the launch of its new product, PR-X 100MG tablets, designed to support prostate health, urinary, and hair needs. The product features natural ingredients combined with high-quality Full-Spectrum CBD Isolate, and has undergone lab testing for potency. CEO Lisa Nelson highlights this launch as a significant step for the company, aimed at driving revenue growth and expanding market reach in Arizona. The press release also notes the extensive benefits of CBD for various health conditions.

CBD Life Sciences (OTC PINK: CBDL) announces the launch of a Mobile CBD Store on Wheels, developed through its subsidiary, LBC Bioscience Inc.

This initiative aims to enhance revenue and growth by allowing the company to sell CBD products at various events across the U.S. The mobile store will offer popular items like pre-rolls, edibles, and CBD beverages. The food truck industry has seen an impressive growth rate of 12.1% annually, indicating strong potential for success in this venture. LBC Bioscience plans to keep shareholders updated on developments.

CBD Life Sciences (OTC PINK:CBDL) is set to launch a novel bladder control supplement via its subsidiary, LBC Bioscience Inc.. This all-natural product will be infused with CBD and aims to aid sleep, relieve stress, and control bladder function. The global cannabidiol market is projected to grow significantly from USD 3,675.1 million in 2022 to USD 55,791.3 million in 2028 at a CAGR of 47.49%. The company remains committed to keeping the public updated as research progresses on this innovative product.

CBD Life Sciences (OTC PINK: CBDL) has announced the launch of its new Green Apple Infused Gummies, featuring 15MG of Delta-8 and 10MG of Delta-9 per gummy. This product reflects the company's commitment to innovation and aims to enhance consumers' focus and mental well-being. Available in stores and soon on the LBC website, these gummies are rigorously tested for quality. The company, led by President & CEO Lisa Nelson, emphasizes its ongoing dedication to product development and shareholder updates through various online platforms.

CBD Life Sciences (OTC PINK:CBDL) announced the launch of its Delta-8 infused snacks through its subsidiary, LBC Bioscience Inc. The snacks come in five varieties, each containing 500MG of Delta-8. This legal cannabinoid is gaining popularity due to its mild psychoactive effects and potential therapeutic benefits. The company aims to maintain a competitive edge by using high-quality ingredients. The CBD market is projected to grow significantly, reaching USD 55.79 billion by 2028, indicating strong demand for cannabinoid products.

CBD Life Sciences (OTC PINK: CBDL) has launched a new laboratory operation at its retail location, CBD Vault, through its subsidiary, LBC Bioscience Inc. This initiative comes in response to increased demand, enabling production of a wide range of products, including tinctures and gummies. CEO Lisa Nelson highlighted that the new ultramodern machinery has quadrupled product development, allowing for large orders and innovations in product offerings. The global CBD market is projected to grow significantly, further driving opportunities for CBDL as consumer interest in therapeutic applications rises.

CBD Life Sciences (OTC PINK: CBDL) is preparing to attend the White Label Expo in Las Vegas from May 25-26, 2022. LBC Bioscience Inc., a subsidiary of CBD Life Sciences, aims to showcase their products and establish connections with key distributors. CEO Lisa Nelson noted the significant revenue generated during their previous participation, highlighting the expo's potential for growth. The event will host over 300 exhibitors and offer insights into innovative techniques and technologies in the industry.

CBD Life Sciences (OTC PINK: CBDL) announced the launch of new Delta-9 Gummies through its subsidiary, LBC Bioscience Inc. The gummies feature a 2:1 blend of CBD and Delta-9, offering 200MG of Delta-9 and 400MG of CBD per serving. This product aims to provide a balanced and calming experience. Consumers can expect availability both in-store and on the LBC website soon. The company is also revamping its e-commerce platform for a better shopping experience. CEO Lisa Nelson expressed excitement about the product launch and future updates.